104.77 USD
▼-2.92-2.71%
盘后 105.28 0.00%
2026-09-15
市值
$5.86B
市盈率
—
EPS
-4.11
股息率
—
52 周区间
32.22 – 117.88
成交量
478.96K
Beta
0.06
目标价
141.21
52W 低 32.2252W 高 117.88
价格走势
公司简介
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...